By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Intercept Pharmaceuticals 

450 W 15th Street
Suite 505
New York City  New York  10011  U.S.A.
Phone: 646-747-1000 Fax: 646-747-1001



Company News
Novartis AG (NVS) Rumored to Be Buying Intercept Pharma (ICPT) 12/29/2016 6:43:20 AM
European Commission (EC) Grants Intercept Pharma (ICPT)’s Ocaliva (Obeticholic Acid) Marketing Authorization For The Treatment Of Primary Biliary Cholangiti 12/14/2016 7:13:56 AM
Intercept Pharma (ICPT) Presents New Data At American Association for Study of Liver Diseases Examining The Effects Of Ocaliva (Obeticholic Acid) On Non-Invasive Assessments Of Liver Fibrosis In Patients With PBC 11/11/2016 7:57:30 AM
Intercept Pharma (ICPT) To Report First Quarter 2016 Financial Results On May 5 11/3/2016 9:15:37 AM
Intercept Pharma (ICPT) Announces Ocaliva (Obeticholic Acid) Data In PBC To Be Presented At The 2016 AASLD Annual Meeting 11/1/2016 8:59:17 AM
Intercept Pharma (ICPT) To Report Third Quarter 2016 Financial Results On November 3 10/31/2016 8:47:36 AM
Intercept Pharma (ICPT) Gains Positive CHMP Opinion for Ocaliva 10/14/2016 7:02:01 AM
Gilead (GILD) Might Avoid Fighting Celgene (CELG), But Allergan (AGN), Intercept Pharma (ICPT) and Novartis AG (NVS) Await 10/3/2016 6:50:53 AM
Intercept Pharma (ICPT) Files New Drug Submission To Health Canada For Marketing Approval Of Obeticholic Acid For The Treatment Of Patients With Primary Biliary Cholangitis 9/19/2016 8:54:36 AM
Intercept Pharma (ICPT) To Present At Upcoming Investor Conferences 9/2/2016 7:46:10 AM